Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 1,241

Document Document Title
WO/2018/211331A1
Disclosed are methods for preparing buprenorphine from, for example, compounds such as nororipavine and northebaine.  
WO/2018/200607A1
Disclosed and described is a novel dose titration procedure for administering the opioid antagonist, nalmefene, to a patient diagnosed with post-traumatic stress disorder (PTSD).  
WO/2018/183264A1
The invention describes pharmaceutical compounds and compositions comprised of a ligand attached to opioids in a manner that substantially decreases or deters the potential for opioid abuse, addiction, illicit and illegal use, and overdo...  
WO/2018/178879A1
A method of recovering a highly pure hydrocodone base from an impure hydrocodone preparation includes contacting the impure hydrocodone preparation with a weak acid in water to form a solution and adding a strong base to the solution in ...  
WO/2018/165183A1
An abuse deterrent opioid formulation for rectal use. The formulation contains a therapeutically effective amount of the opioid buprenorphine or salts and homologs thereof; and either a gel with a diminishing agent or a suppository base ...  
WO/2018/141192A1
The present invention relates to a compound as represented by structural formula (I) and a non-toxic, pharmaceutically acceptable salt thereof. In formula (I), R1 is H, CH3 or deuterated methyl(CD3); R2 is CH3 or CH2CH3; each of R3, R4 a...  
WO/2018/128798A1
Novel antagonists of toll-like receptor 4 (TLR-4) are provided. More specifically, the novel antagonists of TLR-4 are derived from morphinan. Further, use of said morphinan derivatives in the treatment of diseases and/or disorders mediat...  
WO/2018/125716A1
The application is directed to compounds of formula (I): and pharmaceutically acceptable salts, radiolabeled isomers, solvates, or hydrates thereof, wherein R1, R2, R3, X, and n are defined as set forth in the specification. The applicat...  
WO/2018/080838A1
The invention provides haptens and methods of preparation thereof, for producing immunoconjugates of oxycodone and hydrocodone suitable for raising antibodies in animals specific for the opioid drugs. Adminislration of the opioid-speeifi...  
WO/2018/070943A1
The invention describes a method for purification of naltrexone base from reaction mixtures concentrated by evaporation and/ or from mixtures containing naltrexone in the presence of other organic or inorganic substances by trituration a...  
WO/2018/009856A1
Methods are provided for efficient preparation of hydromorphone or hydrocodone by redox isomenzation of morphine or codeine allylic alcohols, respectively, using transition metal aminophosphine catalysts formed in situ.  
WO/2017/218518A1
Compositions and methods for treatment of acute and chronic pain are disclosed herein. These compositions include fixed dose oral formulations containing an atypical antipsychotic drug and an opioid. Also provided here are methods of tre...  
WO/2017/211879A1
The present invention relates to the process for the manufacture of hydrocodone or hydromorphone from their enol derivatives codeine and morphine respectively. Particularly, the invention discloses a metal catalyst that is used in low am...  
WO/2017/210105A1
Peripherally selective compounds that modulate both the mu opioid receptor (MOR) and the kappa opioid receptor (KOR) are provided. The compounds are substituted derivatives of 6p-N-heterocyclic naltrexamine (NAP) and are used in the trea...  
WO/2017/207519A1
The present invention relates to a new process for obtaining 3,14-diacetyloxymorphone from oripavine, a process to transform the obtained 3,14-diacetyloxymorphone into a noroxymorphone and a process to transform said noroxymorphone into ...  
WO/2017/200970A1
Analogues of 6 α/β-naltrexamine (NAQ) are provided. The analogues are selective, reversible antagonists of the mu opioid receptor (MOR) that exhibit good blood brain barrier penetration. The compounds are used in the treatment of opioi...  
WO/2017/184979A1
The present disclosure relates to N-demethylation of a compound containing a tertiary N-methylamine, including for example a morphinan alkaloid, in a continuous flow system. In particular, the present disclosure relates to N-demethylatio...  
WO/2017/185004A1
The present invention relates to processes useful in the preparation of morphine analogs and derivatives, such as naltrexone, naloxone and nalbuphine and intermediates in the synthesis of said morphine analogs and derivatives. In a parti...  
WO/2017/165558A1
The invention provides compounds, compositions, and methods for treating pain.  
WO/2017/133634A1
The present invention relates to an opioid receptor antagonist conjugate and a use thereof. In particular, the present invention relates to a covalent coupling conjugate of a hydrophilic polymer and an opioid receptor antagonist and the ...  
WO/2017/120468A1
The present invention relates to methods for treating pruritus with anti-pruritic compositions, wherein the method provides a therapeutic effect without producing a substantial aquaretic effect.  
WO/2017/095734A1
The invention describes pharmaceutical compounds and compositions comprised of a ligand attached to the opioid oxymorphone, in a manner that substantially decreases or deters the potential for opioid abuse, addiction, illicit and illegal...  
WO/2017/092638A1
The present invention relates to an opioid receptor antagonist derivative, a preparation method thereof and a use thereof in medicine. In particular, the present invention relates to a naloxone derivative as shown by general formula (I) ...  
WO/2017/091827A1
The invention describes pharmaceutical compounds and compositions comprised of a ligand attached to the opioid oxycodone, in a manner that substantially decreases or deters the potential for opioid abuse, addiction, illicit and illegal u...  
WO/2017/073710A1
The purpose of the present invention is to provide a compound that is effective as a prophylactic agent or a therapeutic agent for various diseases and symptoms associated with the orexin receptor, as well as to provide a medical usage t...  
WO/2017/066249A1
An invention includes a process for the preparation of (S)-2((4R,4aS,6R,7R,7aR,12bS)-7,9-dimethoxy-1,2,3,4,5,6,7,7a -octahydro-4a,7-ethano-4,12-methanobenzofuro[3,2-e]isoquinol in-6-yl)-3,3-dimethylbutan-2-ol.  
WO/2017/046814A1
The present invention discloses a short, simplified and eco-friendly process for producing Nalbuphine or its pharmaceutically acceptable salts thereof. In particular, the process of the present invention avoids use of any hazardous, corr...  
WO/2017/041139A1
The present invention relates to compounds and their uses, in particular, compounds in the form of prodrugs that promote transport of a pharmaceutical agent to the lymphatic system and subsequently enhance release of the parent drug.  
WO/2017/040607A1
An abuse deterrent pharmaceutical composition including an acid soluble salt of a pharmaceutically active ingredient and a buffering ingredient; wherein the acid soluble salt of the pharmaceutically active ingredient and the buffering in...  
WO/2017/017436A1
There is provided a novel process for the preparation of a compound of formula (I), wherein R1 is as described in the description, by demethylation of a corresponding O-methyl derivative.  
WO/2016/187522A1
The present invention is directed to a process for the preparation oxymorphone freebase, comprising hydrogenation of 14-hydroxymorphinone in DMF, to yield oxymorphone freebase, preferably oxymorphone freebase of improved appearance, puri...  
WO/2016/181218A1
The present invention provides an abuse deterrent oral fixed-dose composition, comprising a stimulant or opioid and an abuse deterrent active, wherein the abuse deterrent active is configured to be bioavailable only when the composition ...  
WO/2016/169662A1
Crystalline salts of 4,5 α-epoxy-3-methoxy-17-methylmorphinan-6- one tartrate (1:1) (hydrocodone bitartrate) are disclosed and three polymorphic forms of these salts are reported. The invention further relates to a pharmaceutical compos...  
WO/2016/169663A1
Crystalline salts of 7,8-Didehydro-4,5 alpha-epoxy-17-methylmorphinan-3,6 alpha-diol sulfate(2:1), i.e. of morphine sulphate, are disclosed and four polymorphic forms of these salts are reported. The invention further relates to a pharma...  
WO/2016/167318A1
Provided are: a memory-improving agent and memory-improving composition containing as an active ingredient a compound that is an inverse agonist of opioid δ receptors, a pharmacologically acceptable salt thereof, or a solvate of these; ...  
WO/2016/152953A1
The objective of the present invention is to provide an analgesic drug that is a peripherally selective opioid κ-receptor agonist and reduces side effects based on opioid μ-receptor agonists such as drug dependency and respiratory depr...  
WO/2016/154420A1
The present invention relates to new medical uses of morphinans such as naltrexone, nalmefene and their related derivatives. The present invention relates to Toll-like receptor 4 (TLR4) antagonist compounds, and pharmaceutical formulatio...  
WO/2016/142877A1
The present disclosure provides acetate salts of buprenorphine, and its anhydrates, solvates, hydrates, and crystalline forms thereof, where the acetate salts of buprenorphine are essentially free of impurities. The disclosure further pr...  
WO/2016/142506A1
The present invention relates to a method of preparing a compound of Formula II-a' or Formula II-b', wherein RI represents hydrogen or a linear, branched and/or cyclic alkyl or alkenyl group having 1 to 10 carbon atoms; RII represents a ...  
WO/2016/123202A1
An improved method for the preparation of an oxymorphone hydrochloride composition containing less than 10ppm of 14- hydroxymorphinone is provided. The oxymorphone hydrochloride is produced by hydrogenating a starting material comprising...  
WO/2016/100113A2
Compositions, methods, and kits are disclosed directed at haptens, immunogens and immunoassays for oxycodone and metabolites thereof. The compounds are exemplified by compounds of the Formula I. The method comprises providing in combinat...  
WO/2016/078833A1
The invention relates to an improved method of preparing buprenorphine, a salt thereof, analogues of buprenorphine and their salts. In particular, the invention relates to a method of preparing buprenorphine and related products and salt...  
WO/2016/067054A1
There is provided a novel process for the preparation of a hydrocodone salt. In particular, there is provided a novel process for the preparation of a free-flowing slurry of a hydrocodone salt, for example,a free-flowing slurry of hydroc...  
WO/2016/053678A1
The present invention is directed to a method for the extraction and/or enrichment of alkaloids from a mixture containing such compounds. More particularly, the present invention is directed to methods for extracting one or more alkaloid...  
WO/2016/032505A1
Improved processes for making opioid products having low impurity levels including making 14-hydroxycodeinone and 14-hydroxymorphinone from thebaine and oripavine, respectively.  
WO/2016/026048A1
Methods that may be used for the manufacture of a class of chemical compounds known as morphinans, including neopine, are provided. Compositions useful for the synthesis of morphinans, including neopine, are also provided.  
WO/2016/014864A8
The present application relates to compounds of Formula (I): wherein R1 and X are as defined herein, as well as methods for synthesis and use thereof. The present application also relates to 10'-hydroxy-(R),(R)-2,2'-bismethylnaltrexone, ...  
WO/2016/014864A1
The present application relates to compounds of Formula (I): wherein R1 and X are as defined herein, as well as methods for synthesis and use thereof. The present application also relates to 10'-hydroxy-(R),(R)-2,2'-bismethylnaltrexone, ...  
WO/2016/005923A1
The disclosure relates to processes for reducing the amount of a compound of formula (I) or a salt or a solvate thereof present in a composition comprising compounds of formulae (I) and (II) or a salt or a solvate thereof.  
WO/2015/171354A3
The present invention is directed to a process for the preparation of opioid compounds such as buprenorphine, naltrexone, naloxone, nalbuphone, nalbuphine, and the like.  

Matches 1 - 50 out of 1,241